Please ensure Javascript is enabled for purposes of website accessibility
Dow development laboratories, llc is a company specialized in topical drug product manufacturing and formulation. We take pride in providing top-notch services for topical formulation design.
Dow development laboratories, llc is a company specialized in topical drug product manufacturing and formulation. We take pride in providing top-notch services for topical formulation design.
Skincare lab workspace with beakers, a dropper bottle of liquid formulation, a jar of cream, a notepad, and a pen on a sunlit table.

Preformulation: An Important Step in Semi-Solid and Liquid Formulation Design

Preformulation is an important early step in pharmaceutical development. Characterizing the solubility and compatibility of an active pharmaceutical ingredient (API) with potential formulation excipients provides critical information for selecting an appropriate dosage form strategy. This knowledge helps guide the development of a stable drug product that is appropriate for the intended route of administration, disease state, and target site of action. The importance of understanding these API properties and their potential impact on drug product performance is outlined in ICH Q8(R2) Pharmaceutical Development.

Beyond Basic Solubility

Preformulation studies need to go beyond basic solubility information available in an API Safety Data Sheet (SDS). Excipients are selected from the FDA’s IID (Inactive Ingredient Database), which includes the ingredients in approved topical drug products, and are chosen based on the disease state to be treated. While solubility provides an important starting point, formulation development also requires an understanding of how these excipients affect the API.

For semi-solid and liquid formulations, factors such as the API’s solubility in individual or blends of excipients, physical and chemical compatibility (e.g., the potential for degradation or other interactions) influence formulation selection and drug product stability. ICH Q8(R2) specifically recommends evaluating the compatibility of the drug substance with the excipients used in the drug product and considering physicochemical properties that may affect product performance.

Identifying Incompatibilities Early

Identifying potential API–excipient incompatibilities early in development can help reduce the number of formulation candidates carried forward and provide a more informed basis for formulation selection. Excipient characteristics and their potential effects on product quality, stability and performance should be considered as part of the pharmaceutical development process.

Compatibility studies are designed to evaluate the API in the presence of individual and excipient blends under controlled, accelerated conditions. Samples are stored under defined conditions and analyzed at predetermined timepoints using analytical methods to assess changes in the API and identify potential degradation or incompatibility.

The resulting data can help the development team distinguish promising excipients from those that may present compatibility concerns before more extensive formulation development begins. This systematic approach can improve formulation development efficiency and support a science-based rationale for excipient selection.

References

  1. International Council for Harmonisation (ICH). Q8(R2): Pharmaceutical Development. ICH Harmonised Guideline. The guideline identifies solubility and other physicochemical properties of the drug substance as potentially important to drug-product performance and states that drug-substance/excipient compatibility should be evaluated.
  2. International Council for Harmonisation (ICH). M4Q(R1): The Common Technical Document for the Registration of Pharmaceuticals for Human Use – Quality. Section 3.2.P.2, Pharmaceutical Development. The CTD identifies drug-substance/excipient compatibility and relevant physicochemical characteristics as elements of pharmaceutical development.
  3. United States Pharmacopeia (USP). Excipients Research. USP highlights the importance of excipient quality and variability to pharmaceutical product quality.